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occurred in our case.
Atypical presentations of tinea faciei can lead to misdia-
gnosis. The present case underlines that physicians should 
keep in mind that clinical features of superficial fungal 
infection can be substantially modified by incorrect treat-
ment, to mimic even herpes simplex virus infection. Fun-
gal infection should be on the list of differential diagnoses 
of facial eruptions, especially in cases not responding to 
preceding management.
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Dear Editor:
Prostaglandin analogues are increasingly used as the first 
choice of drug for an open angle glaucoma1. They are 
known to be highly effective and have little systemic side 
effects. Latanoprost is an ester prodrug analog of prosta-
glandin F2α which reduces the intraocular pressure by 
increasing the uveoscleral outflow2. Latanoprost 0.005% 
has received the European and the US approval as the 
first-line drug reducing the intraocular pressure in patients 
with open angle glaucoma or ocular hypertension. Aller-
gic contact dermatitis due to latanoprost is rare, although 
it has been commonly used worldwide on patients with 
glaucoma. Only three cases of allergic contact dermatitis 
due to latanoprost have been reported in the English 
literature3-5. Herein we report a case of allergic contact 
dermatitis due to topical eye drops containing latanoprost.
A 70-year-old man presented with an 1-year history of skin 
lesion on both eyelids to our department. He showed 
erythematous oozing patches on both eyelids, and suf-
fered from severe pruritus and burning sensation (Fig. 1). 
He was diagnosed with open angle glaucoma 5 years ago, 
and he has been treated with latanoprost 0.005% (XalatanⓇ; 
Pfizer, New York, NY, USA) and dorzolamide/timolol 
(CosoptⓇ; Merck, Whitehouse Station, NJ, USA). The 
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Fig. 2. Patch test with XalatanⓇ showed positive reaction (right
patch) and patch test with CosoptⓇ showed doubtful reaction 
(left patch) after 48 hours.
Fig. 1. Erythematous oozing patches on the both eyelids.
Pfizer, New York, NY, USA) and dorzolamide/timolol 
(CosoptⓇ; Merck, Whitehouse Station, NJ, USA). The 
patch tests with standard antigens (True TestⓇ; SmartPra-
ctice Denmark, Hillerød, Denmark) were all negative 
except neomycin which showed a weak positive reaction. 
The patch test with latanoprost showed a positive reaction 
(+) showing erythema, edema and papules. And the patch 
test with dorzolamide/timolol showed a doubtful reaction 
(?+) which with only a faint erythema (Fig. 2). Based on 
the patch test results, we confirmed the diagnosis of 
allergic contact dermatitis due to topical eye drops 
containing latanoprost, and the patient changed his 
anti-glaucoma medication. The skin lesions improved 
rapidly with systemic and topical corticosteroid treatment.
Glaucoma is a common eye disorder characterized by 
progressive optic nerve degeneration and changes in the 
visual field. The elevated intraocular pressure is the most 
important risk factor of glaucoma progression1. According 
to the World Health Organization and the Glaucoma 
Foundation, glaucoma is believed to affect between 67 to 
105 million people worldwide2. The maintenance therapy 
with topical anti-glaucoma drug is crucial to prevent a 
permanent visual loss. Currently, prostaglandin F2α ana-
logues are the most commonly used drug for glaucoma 
therapy. There are three main drugs of prostaglandin F2α 
analogues: latanoprost, bimatoprost and travoprost. Lata-
noprost 0.005% is the first line drug for glaucoma in 
Korea as well as in Europe and the United States. The 
common adverse effects of latanoprost are conjunctival 
hyperemia, hypertrichosis and hyperpigmentation, but 
these are only mild and tolerable side effects2. Allergic 
contact dermatitis due to latanoprost may cause pruritic 
skin eruptions although it is a very rare side effect. There 
is a report that a patient was sensitized to latanoprost but 
not to bimatoprost, which is another drug of prostaglandin 
F2α analogues4. Thus, switching the causative drug to 
another anti-glaucoma drug might be a treatment of 
choice. In addition, since bimatoprost 0.03% (LatisseⓇ; 
Allergan, Irvine, CA, USA) is widely used for the treatment 
of eyelash hypotrichosis in the field of dermatology, we 
have to pay attention to the occurrence of contact 
dermatitis due to bimatoprost.
In conclusion, even though there are not many reports, we 
have to be aware of the possibility of allergic contact 
dermatitis due to latanoprost.
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